renal disease, 17 showed rapid progression within 2.5 years after diagnosis. Fifteen of the 17 patients were males; all were severely nephrotic and had impaired renal function at diagnosis. Only 1 of 24 patients with nonnephrotic proteinuria at index renal biopsy progressed to end-stage renal disease. Overall, a level of baseline proteinuria of 10 g or more per 24 hours and variable blood pressure control in hypertensive patients were associated with renal progression.
As a form of primary glomerulopathy with a well-defined histologic appearance, idiopathic membranous nephropathy is most common in adults with the nephrotic syndrome. Although there are distinctive morphologic and immunopathologic characteristics, the glomerular lesion most likely represents a constellation of different disease processes [1, 21. Progression to renal failure varies widely in analyses of large numbers of both untreated and treated patients worldwide [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Variations in clinical course undoubtedly stem from poorly understood causes and pathogenesis. There are also recognized clinical observations of better outcomes, particularly in women [13] , children [5] , and those who have nonnephrotic proteinuria at presentation, as opposed to a worse prognosis in patients who present with the nephrotic syndrome [4, 7, 101 . Association of idiopathic membranous nephropathy with HLA DR3 has been found in populations from England,
[151. On the other hand, patients from England with the haplotype Bl8-BfFI-DR3 had a worse prognosis than others [14] . All of these conditions must be taken into consideration when evaluating the effects of various therapies on clinical outcome.
The treatment of idiopathic membranous nephropathy remains controversial [16, 17] . Eight prospective, controlled, clinical trials have been published, more than in any of the other primary glomerular diseases . Four studies failed to show effectiveness of several treatments [18-2 1] and four reported beneficial effects [22] [23] [24] [25] .
We report our long-term observations on 140 patients with idiopathic membranous nephropathy, 89 of whom did not receive treatment with either corticosteroid or immunosuppressive drugs. Reviewing the natural history of idiopathic membranous nephropathy is particularly important in view of the unsettled issue of therapeutic intervention.
Methods
Selection of patients Renal biopsies from 170 patients with membranous nephropathy who had their index biopsies at the Mayo Clinic between 1972 and 1984 were examined. To ensure a uniform approach to histologic diagnosis, tissue blocks of light microscopic sections and tissue for immunofluorescent-and electron-microscopy were prepared by standard techniques [26] .
Staging of the glomerular morphology by electron microscopy followed that advocated by Ehrenreich and Churg [27] and Churg [28] . and IV were equal, the assignment of the lesion was to the highest category. Five stages of development were defined as follows: Stage I. Small deposits were scattered along subepithelial surfaces of the basement membranes; there were focal confluence of deposits, an absence of rudimentary basement membrane reaction (spikes), and lamina densa of normal thickness.
Stage II. Large numbers of subepithelial deposits (many confluent) were located along most peripheral capillary loops; there were deposits indenting lamina densa and prominent spikes with infrequent incorporation of deposits.
Stage III. There was a large number of subepithelial deposits, prominent incorporation of deposits into thickened lamina densa, and reabsorption of deposits was well-defined.
Stage IV. Stage IV lesions showed markedly thickened lamina densa with variable electron densities and segments of basement membranes which may contain lesions of stage I, II, or III.
Stage V or end-stage. This had capillary wall collapse and global sclerosis with some loops showing lesions of stage I, II, or III.
In seven biopsies electron microscopic examination was not available so that staging of the glomerular lesion was based on assessment of the thin-section light microscopy.
Details of patients
The histories of those patients with histologically defined membranous nephropathy were reviewed. Twenty-four patients were excluded from study for the following reasons: systemic diseases of lupus erythematosus (6) and rheumatoid arthritis (6)-in the latter, associations with gold-salt treatment (3) and gold-salt plus D-penicillamine treatment (2); other disorders including crescentic glomerulonephritis superimposed on membranous nephropathy (2), bullous pemphigoid (2), lymphoproliferative disease (2), cryoglobulinemia (I), idiopathic thrombocytopenic purpura, Coombs'-positive hemolytic anemia, and IgG kappa monoclonal proteinemia (I), myasthenia gravis(1), polyarteritis nodosa(l), pyodermagangrenosum (1), polymyalgia rheumatica and gold-salt treatment (I). Four patients with idiopathic membranous nephropathy were excluded from analysis because they presented with renal failure: three were dialysis dependent and one patient had a serum creatinine level of 8.2 mg/dl and progressed to dialysis treatment in four weeks. No follow-up information after renal biopsy was obtained for two patients. Thus, 140 patients with idiopathic membranous nephropathy comprised the study group. Patients were followed at varying intervals in this retrospective clinical review. Baseline laboratory data at index renal biopsy were analyzed with respect to urinalysis, concentrations of serum creatinine, cholesterol and triglycerides, serum protein electrophoresis, serologies including hepatitis B surface antigen, antinuclear antibodies, CHs), C3, 24-hour creatinine clearance (Car) and total protein excretion, and clearance of iothalamate (C10). Standard techniques of the Mayo Clinic clinical laboratories were used in each instance.
If recent clinical or laboratory data were not available from personal examination at the Mayo Clinic, a local physician or the patient was contacted to ascertain information that included determination of blood pressure; treatments used for hypertension, the nephrotic syndrome, and the glomerulopathy; and return of serum and 24-hour urine samples for measurement of Cr and total urine protein.
Among the 140 patients, 89 were not treated with corticosteroid, immunosuppressive, or other drugs. Fifty-one patients were treated as follows: prednisone alone (33), pre-index biopsy (13) , and post-index biopsy (20) . Prednisone was administered before or in combination with other drugs as follows: meclofenamate (9), oral cyclophosphamide (3), azathioprine (1), and chlorambucil (1). Meclofenamate was used in a prospective study of severe nephrotic syndrome that included nine patients in this review [29] . Nineteen patients were receiving prednisone at the time of their index renal biopsy. Minimal prednisone treatment was with 40 mg/day for one month in two patients; 18 received prednisone at a dosage of 60 mg/day for two months or longer, and the remainder of those who were given prednisone, either alone or combined with an immunosuppressive agent, took 20 to 40 mg/day for 6 to 24 months. Cyclophosphamide alone was given to four patients in a dosage of 2 mg/kg per day for one year [20] .
Hypertension was treated with a wide variety of antihypertensive agents and sodium restriction, usually to less than 90 mEq/day, and various diuretic regimens were given for hypertension and control of edema.
Criteria for patient assessment Particular attention was paid to certain arbitrarily defined criteria of outcome. For renal function: 1) stable (serum creatmine within 0.3 mg/dl from baseline); 2) renal insufficiency (serum creatinine, 2 to 5 mg/dl); and 3) renal failure (serum creatinine, >5 mg/dl). For proteinuria: I) nephrotic syndrome (proteinuria, >3.5 g/24 hr, and lipiduria) or persistent proteinuria (>2 g/24 hr) and 2) remission of nephrotic syndrome (either partial [urine protein, 0.2 to 2 g/24 hrl or complete [urine protein, <0.2 g/24 hr]). For deaths, the date of death and cause were recorded and included a review of autopsy reports when available.
Data analysis
Clinical data forms were completed and the information was placed on magnetic tapes for analysis by using SAS (Statistical Analysis Systems) software. Data were then analyzed in the Section of Medical Research Statistics at the Mayo Clinic (DM1. and C.-P.C.). Patient and kidney survival were estimated by survivorship analysis by using the method of Kaplan and Meier [30] . The relationship of covariates to patient and to kidney survival was investigated univariately with the log-rank test [31] , and multivariately with the Cox proportional-hazards model [32] . Sufficient data to test in the multivariate procedure included age, sex, systolic and diastolic blood pressure, serum creatinine, 24-hour urine protein, serum cholesterol, and triglyceride levels. Discrete variables were compared in untreated and treated groups with ,2 tests, and continuous variables were compared with t-tests or with rank-sum procedures. No. (%) 7 (8) 64 (72) 17 (19) 1 (1) 89 (100) The clinical features of the 140 patients at index renal biopsy are listed in Table 1 . There was a male to female ratio of 2:1; the average age was 50.4 16.8 years, and 24 patients (17%) were less than 30 years old. One hundred sixteen of 140 patients (83%) had the nephrotic syndrome at presentation, including 43 patients (31%) whose baseline proteinuria exceeded 10 g124 hour. Forty-two patients (30%) were hypertensive. One hundred twenty-four patients (89%) were followed from the time of index renal biopsy to current status (within the past 12 months), end-stage renal disease, or death. Follow-up information to current status was incomplete in 16 patients. For the entire study group, follow-up was 0.2 to 14.3 years (mean, 6.2 years; median, 6.1 years).
Histologic staging of the index renal biopsies is shown in Table 2 . The majority of the biopsies were classified as welldeveloped or stage II lesions. To emphasize the overlapping found on electron microscopic examination, 66 biopsy specimens were further designated within major stages as 28 early and 31 late II lesions and 7 late III lesions.
Multiple clinical variables were analyzed between untreated and treated groups (Table 3) and were not significantly different for sex, age, duration of proteinuria, hypertension, stage of the index renal biopsy, or baseline laboratory findings, including serum creatinine level, CCr, Clot, 24-hour urine protein, or levels of serum albumin, total protein, and cholesterol. Mean serum triglyceride level was higher in treated patients (P < 0.05). As there were 19 patients receiving prednisone at the time baseline data were collected, the elevated triglyceride level relates to the effect of corticosteroids on increased lipoprotein production and reduced lipoprotein lipase activity mainly affecting very low density lipoproteins [33] . Patient survival for the total, the untreated, and the treated groups is shown in Figure 1 . The overall survival was 85% at 5 years and 75% at 10 years; these were not significantly different from normal, and there was no significant difference between nontreatment and treatment groups. Survival without death or renal failure was 71% at 5 years, 58% at 10 years, and although about 10 percentage points higher in untreated patients, not significantly different from the treated group (Fig. 2) . The outcome of renal function according to criteria based on serum creatinine data shows no significant differences in the categories of stable, end-stage renal disease, or renal insufficiency outcomes between untreated and treated groups (Table  4) . Overall, for the 140 patients, 90 (64%) remained stable, 28 For the 28 patients who progressed to end-stage renal disease, the values for serum creatinine over time are plotted in Figure 3 . In 17 patients (11 untreated, 6 treated) progression to end-stage renal disease occurred in 2.5 years or less after index renal biopsy. Clinical variables associated with this rapid progression were male gender, elevated serum creatinine levels, and nephrotic syndrome (24-hour urine protein, serum cholesterol, and triglycerides) ( Table 5 ). There were no significant differences between untreated and treated groups. We did not find an association between rapid progression and age, stage of the index renal biopsy, baseline systolic and diastolic blood pressures, serum proteins, Cc., or C1)). Renal function by clearance measurements were made in fewer patients than were estimates by serum creatinine determinations. In the Ii patients with more gradual progression to end-stage renal disease, six were males, five were females, and all were nephrotic at presentation and throughout their clinical course.
By multivariate analysis, serum creatinine and 24-hour urine protein levels (P < 0.01) and serum triglyceride concentrations 7 (10) Nephrotic syndrome 24 (33) Treated, N 42 Remission 17 (40) Persistent proteinuria 5 (12) Nephrotic syndrome 20 (48) a Nephrotic syndrome was intermittent in 17 patients (15%) with various outcomes, including 8 nephrotics, 7 remissions, and 2 with nonnephrotic proteinuria. Urine protein was not quantified for 24-hour measurement in 2 untreated patients so that follow-up information to last analysis is available in 114 patients.
(P < 0.03) remained significantly associated with progression to end-stage renal disease.
The outcome of proteinuria in the 116 nephrotic patients as judged by the defined criteria for patient assessment showed no differences in the nontreatment and treatment groups ( Table 6 ). The majority, or 41 of 72(57%), of untreated patients and 17 of 42 (40%) treated patients had achieved either partial or complete remission from the nephrotic syndrome at final assessment. The nephrotic syndrome was intermittent in 17 patients (15%) who had various outcomes for proteinuria (Table 6) , and proteinuria was variable in 7 (29%) of the 24 patients with baseline nonnephrotic proteinuria. In the nonnephrotic group, 13 of 15 untreated patients and 4 of 9 treated patients were in partial nephrotic remission, S treated patients had nephroticrange proteinuria, and, at last measurement, 2 untreated patients had persistent proteinuria (2.9 g/24 hr). These data indicate the high degree of variability of proteinuria in idiopathic membranous nephropathy when this continuous variable is analyzed long term. Progression to end-stage renal disease was associated with a level of baseline proteinuria of tO g or more per 24 hours (Fig.  4) . By survival analysis, the probability of surviving without renal failure was significantly worse when intervals of proteinuria were compared among the nonnephrotic range (0 to 3.4 g124 hr) and the midnephrotic range (3.5 to 10 g/24 hr) and the severe nephrotic range (10 or more g/24 hr). Only one patient with proteinuria in the nonnephrotic range became persistently nephrotic and developed end-stage renal disease, whereas two others (one untreated and one treated) had renal insufficiency (serum creatinine 2 to 5 mg/dl range) at last follow-up.
Variable blood pressure control in hypertensive patients throughout the clinical course was related to a higher progression rate defined as the development of end-stage renal disease or a doubling of serum creatinine level from baseline (Table 7) (P < 0.05, log-rank test). No difference in the relationship of hypertension and renal progression was noted between the untreated and corticosteroid-or immunosuppressive-treated groups.
Various cancers were found in 10 of 140 patients (7.1%), including six in the treated and four in the untreated groups.
The relationship between diagnosis of the malignancies and the index renal biopsies is shown in Figure 5 .
Twenty-five of 140 patients (18%) died. Sixteen deaths were nonrenal related-lO in the untreated and 6 in the treated group. There were various causes of death: carcinomas (7), cardiovascular (5), and miscellaneous (4). Nine patients died after renal failure was established. In five untreated patients, four had been on long-term dialysis and died of the following: Staphylococcus sepsis (2), with seizures in one; cardiac arrhythmia (I); and cerebrovascular accident (I). One uremic male patient died without support of his renal failure. Four treated patients died, two after being established on dialysis programs, and both after surgery: one from an acutely perforated duodenal ulcer and the other from an ischemic bowel. Two patients died after renal transplantation, one from a ruptured ventricular aneurysm within six months after allografting and a second two years after transplant from acute hepatic necrosis due to recurrent HBs antigen-positive hepatitis.
Discussion
These 140 patients with idiopathic membranous nephropathy had characteristics of male predominance, an average age of 50 years, the nephrotic syndrome in 116 (83%), and hypertension in 42 (30%) when their renal morphologic diagnosis was established. Eighty-nine patients were not treated with corticosteroid or immunosuppressive drugs and 51 patients received mainly short-term treatment with prednisone, usually in a dosage of 60 mg/day for two months. A minority of treated patients also was given meclofenamate or an immunosuppressive agent (mostly cyclophosphamide). The clinical characteristics between untreated and treated patients were similar except for higher serum triglyceride levels in the steroid-treated patients.
Five-year and 10-year patient survival rates were not signit'-icantly different from expected survival nor were they different between untreated and treated groups. Furthermore, survivorship without death or end-stage renal failure combined was similar between untreated and treated patients. We also emphasize that the overall outcomes of renal function and proteinuria were not different between untreated and treated patients, and more than one-half of the patients were in either partial or complete nephrotic remission and had stable renal function at final follow-up. In this retrospective analysis, the different therapeutic regimens may have biased the long-term ineffectiveness of treatment that we observed. An obvious point to underscore here is that treatment effects can only be truly evaluated in well-designed, prospective clinical trials. Hypertensive vs. normotensive progression, P = 0.08 (log-rank test); adequate vs. variable progression, P < 0.005 (log-rank test).
a Doubling serum creatinine level from baseline only (1); end-stage renal disease only (7); doubling serum creatinine + end-stage renal disease (8) b Doubling serum creatinine level from baseline only (I); end-stage renal disease only (7); doubling serum creatinine + end-stage renal disease (6) a Average blood pressure = 140/85 mm Hg or lower.
In analyzing variables at the time of the index renal biopsy, we identified a subset of patients who were at high risk for a rapid progression to end-stage renal disease occurring within 2.5 years after biopsy. These risks were male sex, elevated serum creatinine level, and nephrotic syndrome with an average urine protein excretion of 14.8 g/24 hr. There was a significant correlation between renal progression and increasing levels of baseline protein excretion. Hypertensive patients whose blood pressure was variably controlled had more progressive renal disease. Also, the issue of renal vein thrombosis was addressed in 27 patients included in this review in a previously reported prospective study in which no differences were found in renal progression between those with and without renal vein thrombosis [341.
Concerning the favorable outcomes, the information provided in our review is quite similar to that recently reported in three other series of large numbers of patients with idiopathic membranous nephropathy that included those who were untreated [7, 11, 121 . In the study with the largest number of untreated patients, Noel et al [7] reported that only 10 of 116 patients (9%) developed end-stage renal disease of a total of 22 (19%) who had impaired renal function after an average follow-up of 4.5 years. The low incidence of end-stage renal disease is partly attributed to an inherently improved prognosis found in their population that consisted of nearly 50% females and younger patients, with 25% less than age 20 years at diagnosis. The nephrotic syndrome was present in 76% of the patients at onset. In the two other studies, actuarial 10-year survival rates were 90% in a report from Japan [11] and 83% in a study from Finland [12] . Sixty percent of the Japanese and 75% of the Finnish patients were nephrotic at onset of disease. In both of these studies, there were no differences in patient survival or renal function outcomes between untreated patients and those treated with corticosteroids alone or combined with cyclophosphamide [11, 12] . Previously reported long-term clinical reviews [3] [4] [5] [6] 81 , including one of our own [41, also showed that a majority of patients, regardless of treatment (primarily with glucocorticoids), survived without terminal renal failure. The cumulative results from all of these studies further support the contention that patients with idiopathic inembranous nephropathy have as good a prognosis irrespective of corticosteroid therapy, with or without cyclophosphamide, the predominant cytotoxic drug used, or no treatment other than control of high blood pressure.
Treatment with corticocosteroids or immunosuppressive drugs or both is supported best in two published clinical trials [23, 251 conducted in nephrotic subjects but not necessarily a high-risk population. Renal function was stabilized by the use of alternate-day prednisone treatment (100 to 150 mg in a single dose on alternate days for 2 months) in the collaborative study of the adult nephrotic syndrome [23] and therapy with methylprednisolone (I g intravenously for three days, then the oral preparation at 0.4 mg/kg per day or prednisone 0.5 mg/kg per day) followed by chlorambucil (0.2 mg/kg per day) in monthly cycles for six months in the Italian multicenter trial [25] . Also, in the Italian trial, remissions from the nephrotic syndrome occurred more often in the treated than in the control group in patients primarily with stage I and II lesions [251. Replications are lacking for both of these treatment modalities, although two trials of alternate-day prednisone treatment are under way in Canada 135] and the United Kingdom (Cameron JS, personal communication). In the Canadian trial, treatment with prednisone, 45 mg/rn2 on alternate days for six months, is being compared with controls. In a preliminary report, equal numbers of patients in the treated and control groups had developed end-stage renal disease, but renal function, as assessed by creatinine data, appeared to be more stable in treated patients with stage I and II glomerular lesions [35] . There are no details from the United Kingdom study. Incidentally, we found no relationship between remission rates or progressive renal disease and the composite stage of index renal biopsies.
A major concern in the two fully reported clinical trials is what appears to be a higher than expected progression rate in the control groups. Because of a relatively short follow-up period of two to three years, the continuous variable of a doubling rate of serum creatinine [231 or change in the reciprocal of the plasma creatinine levels [25, 361 was the determinant used for effects of treatment on renal function. A comparison of renal progression by change in serum creatinine level can be made between untreated nephrotic patients in the studies by Noel et aT [7] and the present study and control populations in the clinical trials (Table 8) . For patients at risk after two years, Table 8 . Loss of renal function determined by a doubling of serum creatinine level in nephrotic patients with idiopathic membranous nephropathy after 2 years of treatment versus placebo or control and nontreatment
